ENTRADA THERAPEUTICS, INC. Increase (Decrease) in Long-term Receivables, Current
ENTRADA THERAPEUTICS, INC. (TRDA) reported Increase (Decrease) in Long-term Receivables, Current of -$361.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. increase (decrease) in long-term receivables, current for the quarter ending 2026-06-30 was $29.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in long-term receivables, current for the quarter ending 2026-03-31 was -$390.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in long-term receivables, current for the quarter ending 2025-12-31 was -$19.00K, a 101.76% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in long-term receivables, current for the quarter ending 2025-09-30 was $16.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in long-term receivables, current for fiscal 2025 was -$2.50M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in long-term receivables, current for fiscal 2024 was -$2.20M, a 137.39% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in long-term receivables, current for fiscal 2023 was $5.88M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in long-term receivables, current for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Long-term Receivables, Current 3 month | Increase (Decrease) in Long-term Receivables, Current 6 month | Increase (Decrease) in Long-term Receivables, Current 9 month | Increase (Decrease) in Long-term Receivables, Current 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$361.00K 10-Q · filed 2026-08-05 | -$380.00K derived: sum of 3 quarters · filed 2026-08-05 | -$364.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$390.00K 10-Q · filed 2026-05-07 | -$409.00K derived: sum of 2 quarters · filed 2026-05-07 | -$393.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.00K derived: sum of 2 quarters · filed 2026-02-26 | -$867.00K derived: sum of 3 quarters · filed 2026-08-05 | -$2.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$848.00K derived: sum of 2 quarters · filed 2026-08-05 | -$2.48M 10-Q · filed 2025-11-06 | -$1.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$864.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.50M 10-Q · filed 2026-08-05 | -$1.42M derived: sum of 3 quarters · filed 2026-08-05 | -$6.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.64M 10-Q · filed 2026-05-07 | -$559.00K derived: sum of 2 quarters · filed 2026-05-07 | -$5.63M derived: sum of 3 quarters · filed 2026-05-07 | -$75.47M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.99M derived: sum of 2 quarters · filed 2026-02-26 | -$73.83M derived: sum of 3 quarters · filed 2026-02-26 | -$2.20M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$5.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$74.91M derived: sum of 2 quarters · filed 2025-11-06 | -$3.27M 10-Q · filed 2025-11-06 | -$2.42M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$69.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.80M 10-Q · filed 2025-08-06 | $2.65M derived: sum of 3 quarters · filed 2025-08-06 | $3.93M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $71.64M 10-Q · filed 2025-05-08 | $72.49M derived: sum of 2 quarters · filed 2025-05-08 | $73.77M derived: sum of 3 quarters · filed 2025-05-08 | $71.22M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $853.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.13M derived: sum of 2 quarters · filed 2025-02-27 | -$419.00K derived: sum of 3 quarters · filed 2025-02-27 | $5.88M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$1.27M derived: sum of 2 quarters · filed 2024-11-05 | $5.03M 10-Q · filed 2024-11-05 | $5.03M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $3.74M 10-Q · filed 2024-08-13 | $3.74M derived: sum of 3 quarters · filed 2024-08-13 | $3.74M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $6.30M 10-Q · filed 2024-05-07 | $6.30M derived: sum of 2 quarters · filed 2024-05-07 | $6.30M derived: sum of 3 quarters · filed 2024-05-07 | $6.30M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |